What Раеном Treats: Main Uses and Benefits

The primary therapeutic purpose of Раеном (Ivabradine) is generally considered relevant for providing focused symptomatic relief and support across core areas of chronic heart disease: managing the functional limitations caused by systemic imbalance and assisting with the frequency of chest pain episodes. The medicine is commonly used in these specific, stable conditions.

---

Symptom Relief in Chronic Cardiac Conditions

Раеном is relevant for use in conditions characterized by periods of heightened symptoms, specifically Chronic Stable Angina Pectoris and Symptomatic Chronic Heart Failure (in patients whose condition involves functional stress and a sustained elevated heart rate). It assists with easing physical fatigue and shortness of breath in heart failure, and supports the management of recurrent heart-related chest pain in angina. The treatment offers symptomatic relief that helps patients cope more steadily with difficult episodes.

This application is relevant for patients whose symptoms interfere with daily comfort, and may help reduce the risk of hospitalization for a worsening condition.

Quick Fact: Relief for Cardiac Symptoms
Primary Focus	Managing symptoms related to heightened physiological activity, often linked to an increased resting pulse.
Symptom Type Eased	Physical fatigue, shortness of breath, and recurrent chest pain.
General Benefit	Contributes to improved day-to-day comfort and helps maintain functional stability.

Regulatory References

1. European Medicines Agency (EMA) product information

Official Eligibility and Restrictions

Official regulatory documents define strict criteria for using Раеном (Ivabradine) based primarily on cardiac and physiological status. Eligibility is established for adults with stable chronic heart conditions who are in sinus rhythm and have a resting heart rate ge 70 bpm prior to initiation. Use is also approved for certain pediatric patients aged 6 months and older with stable symptomatic heart failure.

The medicine is contraindicated and must not be used in numerous populations, including patients with a resting heart rate below 70 bpm, severe hypotension (blood pressure < 90/50 mmHg), acute decompensated heart failure, or severe hepatic insufficiency (Child-Pugh C). It is also prohibited for patients with certain conduction abnormalities (e.g., 3^ rd degree AV block), unless a functioning demand pacemaker is present. Use during pregnancy and lactation is also contraindicated, with women of child-bearing potential required to use appropriate contraceptive measures.

Use is generally not recommended for patients with atrial fibrillation or immediately following a stroke. Caution is advised for those with moderate hepatic impairment or severe renal impairment (creatinine clearance < 15 mL/min), and a lower dose should be considered for patients aged 75 years or more.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ivabradine (Раеном) based primarily on its metabolism by the Cytochrome P450 3A4 (CYP3A4) enzyme and its specific heart rate-lowering effect. These interactions mandate strict regulatory restrictions to prevent excessive systemic exposure or enhanced bradycardia.

Co-administration is contraindicated with potent CYP3A4 inhibitors, such as the antifungals Ketoconazole and Itraconazole, certain macrolide antibiotics, and HIV protease inhibitors. The medicine is also contraindicated with the heart rate-reducing calcium channel blockers Verapamil and Diltiazem due to a combination of increased exposure and additive pharmacodynamic effects.

Substances that induce CYP3A4, including the herbal product St. John's Wort (Hypericum perforatum), must be avoided as they can decrease Ivabradine's plasma concentration, potentially compromising efficacy. Consumption of grapefruit or grapefruit juice is also prohibited as it acts as a moderate CYP3A4 inhibitor.

Use with other negative chronotropes, such as Digoxin or Amiodarone, requires close monitoring due to the risk of additive effects on heart rate. Furthermore, the regulatory label specifies that the medicine must be administered with food to ensure the documented systemic exposure is achieved.

Targeting the Heart's Pacemaker Current

Раеном (Ivabradine) functions as a selective inhibitor of the funny current (If), which is generated by Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels located in the heart's natural pacemaker, the sinoatrial (SA) node. The drug binds directly to these channels in a voltage-dependent manner, reducing the flow of the electrical current that initiates each beat. This molecular action modifies the early step in the heart's electrical cycle, which is necessary for the spontaneous firing of the pacemaker cells.

---

⏳ Modulating the Cardiac Rhythm Cascade

The inhibition of the If current specifically slows the rate of spontaneous diastolic depolarization in the SA node. This action prolongs the heart's rest period, known as the diastolic phase, before the next beat is generated. This focused physiological consequence produces negative chronotropy—a reduction in the heart rate. The drug's mechanism does not interfere with the Ca^2+ or K^+ channels responsible for inotropy, thereby isolating the rate-lowering effect. A mechanistic constraint involves the drug's action on similar HCN/Ih channels present in the retina's photoreceptor cells, which results from the same inhibitory mechanism acting on non-cardiac HCN targets.

How to Use Раеном (Ivabradine): Administration Guidelines

Раеном is an oral medicine taken in a twice-daily (BID) regimen, once in the morning and once in the evening, with meals. The primary goal of dosing is to maintain the resting heart rate within a specific therapeutic range, which involves dose adjustment based on regular heart rate monitoring.

Dosage Form & Strength	Standard Dosing Rules
Tablets: 5 mg (scored) and 7.5 mg.	Initial Adult Dose: 5 mg BID. For adults 75 years or older or those with conduction defects, the starting dose is 2.5 mg BID.
Oral Solution: 5 mg/5 mL.	Maximum Dose: The dose must not exceed 7.5 mg BID.

Dosing Frequency and Adjustment

Treatment begins at the starting dose, and the regimen is adjusted after a two-week period based on the resting heart rate. The heart rate is the determinant for any dose change, and adjustments are typically made in 2.5 mg increments (twice daily) to achieve a target range of 50 to 60 beats per minute.

For pediatric patients 40 kg or more, the starting dose is 2.5 mg BID (tablet), while those under 40 kg start with 0.05 mg/kg BID (oral solution). If a dose is missed, the protocol is to skip the missed dose and take the next scheduled dose at the usual time; doses must not be doubled to compensate.

Раеном (Ivabradine): Summary of Clinical Findings

Раеном, which contains the active substance ivabradine, is a heart medicine that has been studied in clinical trials primarily for the management of symptomatic stable angina pectoris (chest pain) and chronic heart failure.

Key Areas of Study

Clinical research has focused on the effect of the substance on the heart rate and its potential role in managing symptoms related to specific cardiovascular conditions.

1. Stable Angina Pectoris

• Heart Rate Reduction: Clinical trials, including randomized controlled trials (RCTs) and meta-analyses, have consistently shown that the active substance in Раеном reduces the heart rate in patients with stable angina whose baseline rate is 70 beats per minute (bpm) or higher.
• Symptom Management: Reductions in the frequency of angina attacks and the need for short-acting nitrates (a common medication for immediate relief) have been observed in studies involving patients receiving the medication.
• Combination Therapy: Studies have explored the use of the active substance in combination with beta-blockers, noting that this approach may lead to sustained reductions in heart rate and anginal symptoms over a follow-up period, compared to treatment with beta-blockers alone.

2. Chronic Heart Failure

• Clinical Outcomes: Large-scale studies involving patients with chronic heart failure (CHF) and a heart rate of 75 bpm or more have been conducted. These studies indicated that the use of the active substance may be associated with improvements in clinical status and reduced hospital admissions related to heart failure progression.

Comparative Data

A small-scale, open-label pilot study comparing the generic product (Раеном) with the original branded ivabradine drug in patients with stable angina found no statistically significant differences between the groups regarding changes in heart rate, blood pressure, or the reported number of weekly anginal attacks. Both groups demonstrated a significant decrease in heart rate, suggesting a similar degree of effect between the two preparations.

Common questions about Раеном (FAQ)

Q: Does Раеном need to be taken with food, or can it be taken on an empty stomach?

Regulatory documents indicate that Раеном can be taken regardless of food intake. This means it can be administered either on an empty stomach or at mealtime, based on the official prescribing information.

Q: Is it safe to drink alcohol while taking Раеном?

According to the official product information, there is no specific mention of a formal contraindication against consuming alcohol while taking Раеном. Patients should consult their healthcare provider regarding the use of alcohol during treatment, as individual circumstances may vary.

Q: Is Раеном a controlled substance or addictive?

The regulatory classification for Раеном, based on official documents, confirms that it is not considered a narcotic or a psychoactive controlled substance. Regulatory guidelines do not classify it as having recognized addiction or abuse potential.

Q: Can I crush, cut, or chew the Раеном tablets instead of swallowing them whole?

Official prescribing information states that Раеном tablets must be swallowed whole with water. They should not be crushed, cut, or chewed. Swallowing the tablet whole is required to ensure it is administered as intended by the manufacturer.

Q: What should I do if I accidentally take two doses of Раеном at the same time?

If an accidental double dose of Раеном is taken, the official product information suggests being aware of potential side effects. Overdose symptoms observed in clinical studies include dizziness, dry mouth, and tremor. Patients experiencing concerning symptoms are advised to contact their healthcare provider or emergency services.

Q: Is it okay to take Раеном if I have kidney problems (renal insufficiency)?

Studies and official information indicate that a modification to the prescribed dose may be necessary for patients with severe renal insufficiency (impaired kidney function). Dose modification is a common regulatory strategy to manage medication levels safely in patients with reduced kidney function.

Q: What is the official storage temperature range for Раеном?

According to the official product information, Раеном should be stored at a temperature not exceeding 25 C (approximately 77 F). Storing the medication within this temperature range is necessary for maintaining product quality as defined by the manufacturer.

Q: Can Раеном be used to treat patients under 18 years old?

Official regulatory documents state that the safety and effectiveness of Раеном have not yet been established for patients who are under 18 years of age. Use in this age group is typically restricted until formal data is available and the indication is approved.

How to Store and Dispose of Raenom (Ivabradine)

Official regulatory information defines specific storage and disposal requirements for Raenom (ivabradine) to ensure product integrity.

Required Storage Conditions

Raenom must be stored at Controlled Room Temperature (20 C to 25 C), with temperatures strictly kept from freezing. Tablets must remain in their original container and be tightly closed to protect against excess heat and moisture. Ivabradine oral solution requires protection from light and must be kept in its foil pouch until use. As a mandatory safety constraint, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Raenom must be disposed of according to local requirements. Any remaining oral solution must be discarded immediately after administration. If local take-back programs are unavailable, the U.S. FDA recommends mixing the medicine with an undesirable substance, sealing it in a bag, and placing it in household trash.